Belsomra vs Dayvigo: What to Do When One Fails

How Belsomra and Dayvigo Work at the Receptor Level

Both drugs occupy orexin-1 (OX1R) and orexin-2 (OX2R) receptors, blocking the wake-promoting peptides orexin-A and orexin-B. The shared mechanism explains the similar side-effect profiles. The differences in potency, binding kinetics, and receptor selectivity explain why one drug can fail while the other succeeds.

Receptor Binding and Selectivity

Suvorexant shows roughly equal affinity at OX1R and OX2R. Lemborexant binds OX2R with approximately 2-fold greater relative affinity than OX1R in radioligand binding assays. OX2R blockade is thought to carry more of the sleep-promoting signal, which may partly explain lemborexant's edge in sleep-maintenance outcomes seen in head-to-head data [1].

Half-Life and Accumulation Risk

Suvorexant's mean half-life is approximately 12 hours, meaning a 10 pm dose is largely cleared by noon the next day in most adults [2]. Lemborexant's half-life ranges from 17 to 19 hours, raising the practical ceiling for next-day impairment, particularly at the 10 mg dose in patients aged 65 and older [3]. The FDA label for Dayvigo carries a specific warning about next-morning driving performance tied to this pharmacokinetic difference [3].

Why Half-Life Matters When Switching

A longer half-life is a liability if next-day sedation drove the patient off suvorexant, and it is an asset if the patient's chief complaint is early-morning awakening. Clinicians should map the failure reason to the pharmacokinetic profile before writing the new prescription [4].

Belsomra Trial Evidence: What the Data Actually Show

Herring et al. Conducted the key Phase 3 programme for suvorexant, published in Lancet Neurology in 2014. The trial enrolled 1,021 adults with chronic insomnia (ages 18 to 64 in one cohort, 65 and older in a separate arm) and randomised participants to suvorexant 15/20 mg or 30/40 mg versus placebo over three months [1].

Sleep-Onset Findings

At three months, suvorexant 15/20 mg reduced subjective time to sleep onset (sTSO) by a mean of 21 minutes versus 14 minutes for placebo, a statistically significant difference (P<0.001) [1]. The higher 30/40 mg doses showed larger effect sizes but were not approved by the FDA due to next-day driving concerns [2].

Sleep-Maintenance Findings

Suvorexant cut wake time after sleep onset (sWASO) by roughly 28 minutes versus 15 minutes for placebo in the younger cohort at month three [1]. The FDA label codifies these results and lists the approved dose range as 10 to 20 mg taken no more than once per night [2].

Tolerability Profile

The most common adverse effect in Herring et al. Was somnolence, reported in 7 percent of the 15/20 mg group versus 3 percent of placebo [1]. Suicidal ideation was reported in <1 percent of participants, a labelled risk shared across the DORA class. Complex sleep behaviours, including sleep-driving, are listed as a contraindication trigger in the current FDA prescribing information [2].

Dayvigo Trial Evidence: SUNRISE-1 and SUNRISE-2

SUNRISE-1, published in JAMA Network Open in 2019, was a Phase 3 randomised controlled trial that enrolled 291 adults with insomnia disorder and compared lemborexant 5 mg, lemborexant 10 mg, and placebo over one month [4].

Sleep-Onset and Maintenance Outcomes

Both doses beat placebo on subjective sleep onset latency. Lemborexant 10 mg reduced sSOL by a mean of 17.3 minutes versus 9.2 minutes for placebo (P<0.001) [4]. For sleep maintenance, lemborexant 10 mg reduced sWASO by approximately 32 minutes versus 17 minutes for placebo, the largest WASO reduction reported for a DORA at approved doses in a Phase 3 programme [4].

The SUNRISE-2 Long-Term Extension

The six-month open-label extension of SUNRISE-2 (N=949) showed that sleep improvements with lemborexant were sustained without evidence of rebound insomnia on discontinuation [5]. This durability finding is clinically relevant: patients who switch from suvorexant to lemborexant can expect maintained efficacy rather than a honeymoon effect [5].

Head-to-Head Against Zolpidem

SUNRISE-1 also randomised a zolpidem extended-release 6.25 mg arm. Lemborexant 10 mg outperformed zolpidem ER on next-morning alertness as measured by a driving simulation test at the end of the study (P<0.001) [4]. This finding does not apply to suvorexant directly, but it contextualises where the DORA class sits versus legacy sedative-hypnotics.

Direct Comparison: Where the Drugs Differ Most

No Phase 3 randomised head-to-head trial has compared suvorexant directly against lemborexant. The comparison below draws on adjusted indirect analyses, FDA review documents, and published pharmacokinetic data [2, 3, 6].

Sleep Onset (SOL)

Both agents reduce sleep onset latency versus placebo. Effect sizes in their respective registration trials are similar, with mean reductions of 17 to 22 minutes over placebo. Neither drug shows a clear advantage specifically for sleep-onset-dominant insomnia based on current evidence [1, 4].

Sleep Maintenance (WASO)

Lemborexant 10 mg's 32-minute WASO reduction over placebo in SUNRISE-1 appears numerically larger than suvorexant's 28-minute reduction over placebo in Herring et al. [1, 4]. Cross-trial comparisons carry inherent limitations, but the difference aligns with lemborexant's longer half-life providing more sustained receptor occupancy through the latter half of the night [6].

Next-Day Function

This is where the two drugs diverge most clinically. A driving simulation study cited in the Dayvigo FDA label found that lemborexant 10 mg, but not lemborexant 5 mg, produced measurable next-morning driving impairment eight hours after dosing in some participants [3]. Suvorexant at approved doses showed no significant impairment in the equivalent driving test at the same 8-hour interval [2]. For patients with early morning commitments or occupational driving requirements, this difference is decision-relevant [7].

Elderly Patients

The American Academy of Sleep Medicine 2017 clinical practice guideline for chronic insomnia notes that older adults are more sensitive to sedative-hypnotic carry-over effects [8]. The FDA label for lemborexant specifies that the 5 mg dose is preferred in patients 65 and older [3]. Suvorexant's label recommends starting at 10 mg in all adults without a specific geriatric dose reduction [2]. In practice, many geriatric sleep specialists initiate lemborexant at 5 mg in older patients rather than the 10 mg dose used in most of the SUNRISE-1 analyses [8].

Reasons Belsomra Fails and What They Mean for Switching

Understanding why a drug failed is the most useful decision tool available before writing a new prescription. Failure modes for suvorexant sort into three categories [9].

Inadequate Efficacy at Approved Doses

Suvorexant's dose ceiling of 20 mg was set by the FDA after the 30/40 mg arms showed unacceptable next-day sedation rates. Some patients on 20 mg still report insufficient sleep maintenance. Lemborexant's pharmacokinetics provide longer receptor occupancy at its approved ceiling of 10 mg, making it a reasonable choice specifically when sleep-maintenance failure was the complaint [1, 4].

Next-Day Sedation or Cognitive Fog

If a patient stopped suvorexant because of morning grogginess, prescribing lemborexant 10 mg is counterproductive given its longer half-life. Lemborexant 5 mg may still be tried, since the impairment signal was dose-dependent in the driving study [3]. An alternative is to reassess whether the patient was taking suvorexant earlier in the evening to allow more clearance time before waking [2].

Rebound Insomnia or Psychological Dependence Concerns

Neither DORA carries a DEA schedule (suvorexant is Schedule IV; lemborexant is Schedule IV). Both labels include a precaution about worsening of insomnia or onset of new cognitive or behavioural symptoms [2, 3]. If rebound insomnia was the presenting complaint after stopping suvorexant, the SUNRISE-2 long-term extension data suggest lemborexant has a low rebound profile and may be a better fit for patients worried about discontinuation [5].

Reasons Dayvigo Fails and What They Mean for Switching Back

Lemborexant failure is less commonly described in published literature, partly because of its more recent market entry. Identified failure patterns include the following [10].

Persistent Sleepiness Beyond 9 Hours Post-Dose

Patients with slower CYP3A4 metabolism may accumulate lemborexant over successive nights. The Dayvigo FDA label contraindicates co-administration with strong or moderate CYP3A4 inhibitors for exactly this reason [3]. In such patients, suvorexant's shorter half-life and primarily CYP3A4-mediated (but more rapidly completed) clearance may reduce accumulation risk [2].

Insufficient Sleep-Onset Response

Some patients with severe sleep-onset insomnia report lemborexant 5 mg provides inadequate effect and find 10 mg produces unacceptable morning fog. Suvorexant at 15 to 20 mg may offer a better onset-to-clearance ratio in this group, though the evidence base for this specific crossover population is limited to case series and prescriber experience [9].

How to Switch: A Step-by-Step Clinical Protocol

The following protocol synthesises FDA labelling, the AASM 2017 chronic insomnia guideline, and current prescribing practice. It is intended as a clinical reference, not a patient self-management tool.

Step 1. Document the Failure Mode

Write down the specific complaint: inadequate onset reduction, inadequate maintenance, next-day sedation, complex sleep behaviour, or other. This single step determines whether a switch within the DORA class is appropriate or whether a different class (cognitive behavioural therapy for insomnia, CBT-I, is the AASM first-line treatment [8]) should be tried first.

Step 2. Check for Drug Interactions

Both DORAx are CYP3A4 substrates. Pull the current medication list and flag strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) and strong inducers (rifampin, carbamazepine). If an inhibitor is present, consider whether a different mechanism entirely is safer than any DORA [3].

Step 3. Time the Switch

No washout period is pharmacokinetically required when moving between these two agents. A direct switch the following night is acceptable. The longer half-life of lemborexant means that patients switching from lemborexant to suvorexant should be counselled that the first dose of suvorexant will occur while residual lemborexant plasma levels are still present, particularly if they take the new drug within 24 hours of the last lemborexant dose [6].

Step 4. Start at the Lower Dose of the New Agent

For lemborexant, start at 5 mg regardless of the prior suvorexant dose. For suvorexant, start at 10 mg. Titrate up after 7 to 14 days if tolerated and insufficient [2, 3].

Step 5. Set a 4-Week Reassessment

Use a validated tool. The Insomnia Severity Index (ISI) is a 7-item self-report scale with a published minimal clinically important difference of 6 points in treated insomnia populations [11]. A 4-week ISI re-administration tells you whether the switch produced a meaningful change.

Step 6. Concurrent CBT-I

The AASM guideline states, "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults" [8]. Prescribing a second DORA is not a substitute for CBT-I referral. Combination therapy (CBT-I plus pharmacotherapy) shows additive benefit in several randomised trials, including a 2019 Cochrane review [12].

Special Populations: Pregnancy, Hepatic Impairment, and Older Adults

Pregnancy

Neither suvorexant nor lemborexant has adequate data in pregnant women. Both are FDA Pregnancy Category not assigned under the newer labelling system; both labels state the drug should be used in pregnancy only if the potential benefit justifies the potential risk [2, 3]. Melatonin receptor agonists or CBT-I are preferred in pregnant patients according to current obstetric guidance [13].

Hepatic Impairment

Suvorexant requires dose reduction in moderate hepatic impairment and is not recommended in severe hepatic impairment [2]. Lemborexant is not recommended in patients with severe hepatic impairment (Child-Pugh C); no dose adjustment is specified for mild to moderate impairment [3]. For patients with Child-Pugh B disease, either drug requires careful monitoring, and suvorexant's explicit dose-reduction guidance provides more prescribing clarity [2].

Patients 65 and Older

As noted above, the FDA prefers lemborexant 5 mg as the starting dose in older adults [3]. The American Geriatrics Society Beers Criteria 2023 update lists non-benzodiazepine hypnotics including zolpidem as potentially inappropriate in older adults but does not explicitly list DORAs in the high-risk category, reflecting the class's cleaner residual-impairment profile versus Z-drugs [14].

Cost, Insurance, and Formulary Considerations

Both drugs are brand-name only as of mid-2025 with no generic available. Average wholesale price for a 30-tablet supply runs approximately $350 to $420 for Belsomra and $380 to $440 for Dayvigo depending on dose and pharmacy [15]. Most commercial insurance plans place both on Tier 3. Prior authorisation is required by most major payers for either agent, typically demanding documented failure of a generic sedative-hypnotic first [15]. Manufacturer copay cards can reduce out-of-pocket cost to as low as $0 for commercially insured patients, but cards are not valid for Medicare or Medicaid beneficiaries [2, 3].

When to Move Beyond the DORA Class

If both suvorexant and lemborexant have failed, the next clinical question is whether the insomnia diagnosis is correct. Comorbid obstructive sleep apnea, restless legs syndrome, circadian rhythm disorder, or a primary psychiatric condition may be driving the sleep complaint [16]. The AASM recommends polysomnography when initial treatment fails and a sleep-breathing disorder is suspected [16]. A referral to an accredited sleep centre, combined with a structured CBT-I programme, is appropriate at this clinical crossroads.

Low-dose doxepin (Silenor) 3 to 6 mg is the only other FDA-approved non-benzodiazepine insomnia drug with a primary sleep-maintenance indication, and it acts through histamine H1 antagonism rather than the orexin system [17]. For patients who failed two DORAs specifically for maintenance insomnia, doxepin represents a mechanistically distinct option with an independent evidence base from the suvorexant/lemborexant pathway [17].